Pasithea Therapeutics (KTTA) Change in Accured Expenses (2021 - 2026)

Pasithea Therapeutics has reported Change in Accured Expenses for 6 years, with the latest figure at $358381.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 73.93% year-over-year to $358381.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $163560.0 (up 114.76% YoY) and the FY2025 annual result came in at $11233.0, up 100.78% from the prior year.
• Change in Accured Expenses climbed to $358381.0 in Q1 2026 per KTTA's latest filing, from -$206697.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $682903.0 in Q4 2023 and troughed at -$1.0 million in Q2 2024.
• A 5-year average of $44344.2 and a median of $30384.0 in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses surged 1437.84% in 2023, then tumbled 1572.63% in 2024.
• Over 5 years, Change in Accured Expenses stood at $280153.0 in 2022, then soared by 143.76% to $682903.0 in 2023, then slipped by 29.22% to $483373.0 in 2024, then plunged by 142.76% to -$206697.0 in 2025, then jumped by 273.38% to $358381.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $358381.0, -$206697.0, and -$243700.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.